BioLife Solutions (NASDAQ:BLFS – Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect BioLife Solutions to post earnings of $0.05 per share and revenue of $29.13 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. The business had revenue of $28.47 million for the quarter, compared to analysts’ expectations of $27.80 million. On average, analysts expect BioLife Solutions to post $0.03 EPS for the current fiscal year and $0.16 EPS for the next fiscal year.
BioLife Solutions Price Performance
NASDAQ BLFS opened at $38.61 on Tuesday. BioLife Solutions has a 52 week low of $17.86 and a 52 week high of $39.76. The firm has a market capitalization of $1.89 billion, a P/E ratio of 33.28 and a beta of 1.82. The company has a 50-day moving average price of $37.56 and a 200-day moving average price of $28.02.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on BLFS shares. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, September 21st. Stephens cut shares of BioLife Solutions from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $32.00 to $31.00 in a report on Monday, July 27th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. Lake Street Capital cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the stock from $33.00 to $31.00 in a research note on Wednesday, July 22nd. Finally, William Blair set a $31.00 price objective on shares of BioLife Solutions in a research report on Thursday, July 23rd. One investment analyst has rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $31.38.
Get Our Latest Analysis on BLFS
BioLife Solutions Company Profile
BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.
The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.
See Also
- Five stocks we like better than BioLife Solutions
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
